TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02479711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: composite restoration
Description: The tooth will be isolated with cotton rolls and the caries will be removed. Enamel and dentin conditionings were performed with a self-etching adhesive system (Adhese One F, Ivoclar Vivadent, Liechtenstein). Bulk fill composite (Tetric EvoCeram® , Ivoclar Vivadent, Liechtenstein) will be injected in a single bulk increment of less than 4 mm to fill the preparations. The material was condensed with a flat instrument. Once set, it will be polished with finishing cups (Enhance® , Dentsply , Milford, USA). An interproximal strip will be used to finish the final contour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glass ionomer cement
Description: The tooth will be isolated wit cotton rolls and the caries will be removed. The dentist will mix and handle the materials in accordance with the manufacturers' instructions. The material was condensed with a flat instrument. Once set, it will be polished. An interproximal strip will be used to finish the final contour. G-Coat Plus (GC, America) will be applied to the surface and margins of the restoration.
Study: NCT03827278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: 6mg/kg bid, was given on the first day, followed by intravenous 4mg/kg bid for 6 days, followed by oral Valconazole 200mg bid for at least 6 months.~Amphotericin B sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until CD4+ T cells are greater than 100 cells/L for at least 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: 6mg/kg bid, was given on the first day, followed by intravenous 4mg/kg bid for 6 days, followed by oral Valconazole 200mg bid for at least 6 months.~Amphotericin B sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until CD4+ T cells are greater than 100 cells/L for at least 6 months
Study: NCT00628433

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HE3286
Description: daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HE3286
Description: daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HE3286
Description: daily for 28 days
Study: NCT00628433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HE3286
Description: daily for 28 days
Study: NCT03917420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 300Mg Oral Tablet
Description: Once daily dose of the combo tab x 5 days pre-sampling
Study: NCT03427203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Mio
Description: SenSura Mio is a marked ostomy device which is used as the comparator in this study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Mio
Description: SenSura Mio is a marked ostomy device which is used as the comparator in this study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Ostomy device 1
Description: Coloplast Ostomy device 1 a newly developed ostomy device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Ostomy device 1
Description: Coloplast Ostomy device 1 a newly developed ostomy device
Study: NCT03917420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine 200 MG
Description: Once daily dose of the combo tab x 5 days pre-sampling
Study: NCT03427203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Ostomy device
Description: Coloplast Ostomy device 2 a newly developed ostomy device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Ostomy device
Description: Coloplast Ostomy device 2 a newly developed ostomy device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Ostomy device 3
Description: Coloplast Ostomy device 3 a newly developed ostomy device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Ostomy device 3
Description: Coloplast Ostomy device 3 a newly developed ostomy device
Study: NCT02327949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: W-Shaped Angular Plate
Description: Treatment of posterior wall fracture of the acetabulum with a W-Shaped Angular Plate
Study: NCT04477343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: Allosteric inhibitor to human CXCR1 and CXCR2 receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injectable Product
Description: humanized monoclonal antibody to program cell death receptor 1 (PD1)
Study: NCT01883687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Septoplasty
Study: NCT02128191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ibuprofen
Description: Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
Study: NCT04398069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hemodynamic optimisation aiming to achieve normal cerebral perfusion
Description: hemodynamic optimisation aiming to achieve normal cerebral perfusion: titration of catecholamin infusion.
Study: NCT01814306

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supreme LMA
Description: Use Supreme LMA to compare efficay with Proseal LMA in prone position insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proseal LMA
Description: Use Proseal LMA to compare efficay with Supreme LMA in prone position insertion
Study: NCT02800083

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02327949

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reconstruction Plate
Description: Treatment of posterior wall fracture of the acetabulum with a Reconstruction Plate
Study: NCT03971773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypnosis
Description: patient with cancer will undergo sessions of hypnosis
Study: NCT01968473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES Device comfort
Description: NMES device, establishing Sensory, Motor and Pain thresholds and Pain tolerance.
Study: NCT00622388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg
Study: NCT03909035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication therapy management
Description: The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~* A patient-pharmacist interview to collect comorbidities, medication, laboratory results, self-medication, adherence, medication patient's knowledge.~* A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~* Detailed feedback to the general practitioner.~* An appointment with the patient to explain the modifications made by the general practitioner (GP)
Study: NCT02068287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: After, at least six hours of hemodynamic optimization, patients with an hyper dynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 20% reduction in heart rate. This infusion is maintained for six hours.
Study: NCT03432559

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: endoscopy
Description: endoscopy of pharynx, upper esophagus, mid esophagus, cardia, gastric fundus, und gastric body
Study: NCT03194113

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma-focused treatment
Description: Weekly sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma-focused treatment
Description: Weekly sessions
Study: NCT01248923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-520, KSP(Eg5) inhibitor; intravenous
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
Study: NCT03616288

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: thiamine (as thiamine hydrochloride)
Description: Opaque capsules containing varying amounts of thiamine hydrochloride and cellulose filler. All thiamine is delivered as thiamine hydrochloride, calculated using a 1.271 correction factor (ratio of molecular weights of thiamine hydrochloride and thiamine).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: thiamine (as thiamine hydrochloride)
Description: Opaque capsules containing varying amounts of thiamine hydrochloride and cellulose filler. All thiamine is delivered as thiamine hydrochloride, calculated using a 1.271 correction factor (ratio of molecular weights of thiamine hydrochloride and thiamine).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: thiamine (as thiamine hydrochloride)
Description: Opaque capsules containing varying amounts of thiamine hydrochloride and cellulose filler. All thiamine is delivered as thiamine hydrochloride, calculated using a 1.271 correction factor (ratio of molecular weights of thiamine hydrochloride and thiamine).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: thiamine (as thiamine hydrochloride)
Description: Opaque capsules containing varying amounts of thiamine hydrochloride and cellulose filler. All thiamine is delivered as thiamine hydrochloride, calculated using a 1.271 correction factor (ratio of molecular weights of thiamine hydrochloride and thiamine).
Study: NCT04602858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reactive Balance Training
Description: Reactive balance training involves the use of the Trip and Slip walkway that is able to expose participants to unpredictable trips and slips. Trips and slips will occur at random location on the walkway and times within the gait cycle, with the participants receiving 3-monthly retraining sessions along with an educational booklet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control intervention will be receiving an educational booklet as part of standard care. The education component will target a variety of fall risk factors and provide strategies to mitigate these risk factors.
Study: NCT03194113

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion regulation training
Description: Managing and tolerating negative emotions, e.g. anger, sadness. Weekly sessions; preparatory to Prolonged exposure treatment
Study: NCT03695731

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold induced activation of brown adipose tissue
Description: cold exposure wearing a cold life jacket

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold induced activation of brown adipose tissue
Description: cold exposure wearing a cold life jacket
Study: NCT02717481

Intervention type: DEVICE
Intervention: US-CT Fusion examination
Description: Patients will undergo an US examination using an US device with US-CT Fusion capabilities.
Study: NCT01248923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib, proteasome inhibitor; intravenous or subcutaneous
Description: Part 1: standard of care; Part 2: standard of care determined in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib, proteasome inhibitor; intravenous or subcutaneous
Description: Part 1: standard of care; Part 2: standard of care determined in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, steroid; oral
Description: Part 1: standard of care; Part 2: standard of care determined in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, steroid; oral
Description: Part 1: standard of care; Part 2: standard of care determined in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Description: Part 1: standard of care; Part 2: standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Description: Part 1: standard of care; Part 2: standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-520, KSP(Eg5) inhibitor; intravenous
Description: Part 1: multiple dose, escalating

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib, proteasome inhibitor; intravenous or subcutaneous
Description: Part 1: standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Description: Part 1: standard of care
Study: NCT01212627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: Ridaforolimus 20 Daily, 5 days each week, (Mon-Fri) on a 28 day cycle
Study: NCT02793531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable isotope amino acid infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable isotope amino acid infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
Study: NCT01177943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Administered orally, once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Administered orally, once.
Study: NCT03194113

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Trauma-focused treatment
Description: Intensive version (3 sessions per week) of Trauma-focused treatment
Study: NCT00855049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Intranasal acetaminophen administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Oral acetaminophen administration
Study: NCT03905850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: 5 mg/1.5 ml and 10 mg/1.5 ml doses administered s.c. (subcutaneously, under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: 5 mg/1.5 ml and 10 mg/1.5 ml doses administered s.c. (subcutaneously, under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: 5 mg/1.5 ml and 10 mg/1.5 ml doses administered s.c. (subcutaneously, under the skin)
Study: NCT01500668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
Study: NCT01514968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: Single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: Single oral dose
Study: NCT02206958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Defeating Urinary Incontinence with Exercise Training
Description: 12 week multi-component program. Continence program administered by a nurse practitioner during 4 home visits. Participants do pelvic floor muscle exercises 5 days/week using a 13-minute instructional audio CD. Based on participant symptoms and preferences the following strategies are taught: bladder training, urge and suppression techniques, caffeine reduction, eliminating bladder irritants, medication adjustment, adequate fluid intake, constipation management, and reducing nocturia.~2. Physical activity program including moderate intensity walking (30 minutes, 5 days weekly) and twice weekly group strength training sessions using Therabands led by a trained exercise instructor.
Study: NCT04548518

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GPO Tri Fluvac vaccine
Description: Each dose of Tri Fluvac contains a total of 45 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection. Tri Fluvac is manufactured and formulated into a multiple-dose vial vaccine (2 doses) using thimerosal at relatively low concentration as preservative (≤ 5.75 μg mercury/ dose). Each 0.5 ml dose of vaccine may contain residual amounts of ovalbumin (≤ 1.0μg), formaldehyde (≤ 100μg), tween 80 (≤ 0.9μg), triton x-100 (≤0.05μg) and gentamicin (≤0.075μg).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed influenza vaccine
Description: The comparator licensed influenza vaccine is a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020
Study: NCT02206958

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Defeating Urinary Incontinence with Exercise Training
Description: 12 week multi-component program. Continence program administered by a nurse practitioner during 4 home visits. Participants do pelvic floor muscle exercises 5 days/week using a 13-minute instructional audio CD. Based on participant symptoms and preferences the following strategies are taught: bladder training, urge and suppression techniques, caffeine reduction, eliminating bladder irritants, medication adjustment, adequate fluid intake, constipation management, and reducing nocturia.~2. Physical activity program including moderate intensity walking (30 minutes, 5 days weekly) and twice weekly group strength training sessions using Therabands led by a trained exercise instructor.
Study: NCT03892460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation
Description: bilateral quadriceps exercise with neuromuscular electrical stimulation
Study: NCT00499733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 500 mg/m\^2 of cyclophosphamide is infused via intravenous route three days post cryoablation surgery.
Study: NCT01338857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar)
Description: Sorafenib (in tablet form) will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.~Children/adolescents (\< 18 years of age, non-NF1): 200 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 400 mg PO twice daily~Adults (greater than or equal to 18 years of age, non-NF1): 400 mg PO twice daily~NF1 patients (regardless of age): 80 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 150 mg PO twice daily
Study: NCT02283788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Study: NCT00499733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Per treating physician's discretion, largest and most accessible lesion will be treated with cryoablation surgery on day 0 of the study.
Study: NCT05648305

Intervention type: PROCEDURE
Intervention: Root Canal Treatment/ Re-treatment
Description: The provision of Root Canal Treatment for teeth with Endodontic infection or to prevent Endodontic infection.
Study: NCT02283788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03704714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT02587845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (IV)
Description: IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
Study: NCT03704714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT00746941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mefloquine
Description: 250 mg orally each day for 3 days and then weekly up to 6 months.
Study: NCT02587845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (Topical)
Description: Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
Study: NCT02918851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfusion of 7-day stored red blood cells
Description: Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 5 (7-day old) red blood cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfusion of 28-day stored red blood cells
Description: Subjects will donate blood at Week 2 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 2 (28-day old) red blood cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfusion of 42-day stored red blood cells
Description: Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week0 (42-day old) red blood cells.